Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Momelotinib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Momelotinib: Sponsors, patents, clinical trial progress

Momelotinib is an investigational drug.

There have been 13 clinical trials for Momelotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Thrombocytosis, Thrombocythemia, Essential, and Primary Myelofibrosis. The leading clinical trial sponsors are Gilead Sciences, Fred Hutchinson Cancer Research Center, and National Heart, Lung, and Blood Institute (NHLBI).

There are twenty-seven US patents protecting this investigational drug and three hundred international patents.

Recent Clinical Trials for Momelotinib
Extended Access of Momelotinib in Adults With MyelofibrosisGilead SciencesPhase 2
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Gilead SciencesPhase 2
Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseGilead SciencesPhase 1

See all Momelotinib clinical trials

Clinical Trial Summary for Momelotinib

Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib

See all Momelotinib clinical trials

US Patents for Momelotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Momelotinib   Start Trial Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Start Trial
Momelotinib   Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Momelotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Momelotinib Argentina 096246 2033-05-09   Start Trial
Momelotinib Australia 2014262622 2033-05-09   Start Trial
Momelotinib Brazil 112015028017 2033-05-09   Start Trial
Momelotinib Canada 2911408 2033-05-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.